Alteogen said on the 2nd that it filed an international patent (PCT) for a formulation technology that can develop a high-concentration biosimilar (copycat drug) of the eye disease treatment "Eylea."
Formulation technology is not about the drug's active ingredient itself, but about how to create the drug's form and concentration so it can be delivered safely and effectively to the body. In particular, because ophthalmic treatments are injected directly into the eye, it is important that the drug remains stable without shaking or deterioration.
Alteogen expects that the patented formulation technology will boost the competitiveness of biosimilars already approved, while also expanding into the development of high-concentration ophthalmic treatments going forward.
A company official said, "This patent is based on the experience gained while developing the Eylea biosimilar 'Iluxvi,' for which Alteogen has already received marketing authorization in Europe," and added, "We will continue to strengthen our technology base in line with the market trend of improving both patient convenience and treatment efficacy at the same time."